Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Do you tell your patients with epithelioid subtype mesothelioma following gross resection and adjuvant cis/pemetrexed that they have completed "curative intent" treatment?
Related Questions
Would you consider the combination of amivantamab and lazertinib in a patient with NSCLC harboring an EGFR exon 19 deletion that transformed to small cell carcinoma on osimertinib, if resistance profiling still detects the EGFR mutation?
For a patient with NSCLC and a targetable mutation that transforms into SCLC, would you immunotherapy to chemotherapy?
How do you approach duration of immunotherapy in patients with metastatic NSCLC?
Would you consider using Elahere for patients with FOLR1-positive metastatic lung adenocarcinoma?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Would you provide vitamin B12 supplementation to a patient on pemetrexed therapy if their B12 levels are normal or high?
Which patients with metastatic NSCLC with an EGFR mutation would you treat with chemotherapy & osimertinib or amivantamab & lazertinib, and how would you choose between the two regimens?
Would you add immunotherapy to chemotherapy for a patient with metastatic NSCLC, an atypical EGFR mutation, and PD-L1 ≥50% who has progressed on Osimertinib?
How do you approach stage IIa squamous cell carcinoma of the lung with a PD-L1 level of 1-49% and no targetable mutations?
Is concurrent immuno-radiation therapy a viable treatment option for patients with unresectable, non-metastatic, locally advanced lung cancer, who have high PD-L1 expression and no oncogenic mutations?
